Scientists re-engineer Patients' own immune cells to hunt down leukemia
NCT ID NCT06424340
Summary
This early-stage trial is testing a new cell therapy for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Doctors will collect a patient's own immune cells (T cells), genetically modify them in a lab to better recognize and attack the leukemia cells, and then infuse them back into the patient. The main goals are to find a safe dose and see if this personalized approach can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Leiden University Medical Center
RECRUITINGLeiden, 2333, Netherlands
Contact
Conditions
Explore the condition pages connected to this study.